DEA Pursues Vast Expansion of Patient Surveillance

DEA Pursues Vast Expansion of Patient Surveillance

DEA Pursues Vast Expansion of Patient Surveillance

https://filtermag.org/dea-expand-patient-surveillance/amp/

The Drug Enforcement Administration (DEA) is looking to expand its anti-diversion surveillance infrastructure by being able to search and analyze myriad patient behaviors for the vast majority of controlled and scheduled drug prescriptions—all accompanied by a rapid process for legally unveiling personally identifying information.

In early September, the agency requested proposals for the creation of software capable of searching at least 85 percent of all US residents’ controlled-substance prescriptions for certain patient behaviors, as well as prescriber and pharmacist practices.

The Pharmacy Prescription Data system would cede patient-level data to the federal drug-war agency to a far greater extent than comparable existing databases.

According to the agency’s request for proposal (RFP), the DEA is interested in its agents having “unlimited access to patient de-identified data” on re/filled prescriptions, daily supply, payment type, dosing information and gender, among other characteristics, until at least 2025.

At publication time, the DEA had not responded to Filter‘s request for comment. This article will be updated if comment is received.

The Pharmacy Prescription Data system, as the RFP calls it, would cede patient-level data to the federal drug-war agency to a far greater extent than comparable existing databases. The current Automated Reports and Consolidated Orders System (ARCOS), created by the Controlled Substances Act alongside the DEA itself, only monitors controlled substances’ manufacture, supply chains and distribution.

RFP for DEA’s Prescription Data Software

The DEA’s desired ability to search controlled-substance prescriptions to this degree targets seemingly mundane behaviors—like the number of times a patient paid in cash for a Schedule II substance like Adderall or OxyContin, or the geographic distances between patients and their prescribers and pharmacies.

But it also subjects people prescribed medications for opioid use disorder (OUD) to even more surveillance than is currently the case. In particular, the Pharmacy Prescription Data system would allow the DEA to track patients by their “Number of Opiate and Buprenorphine combinations.”

Buprenorphine patients’ records have already been available to some state law enforcement, if such agencies operate a state’s prescription drug monitoring program (PMDP). As of August 2020, a new federal regulation permits patients’ methadone records to be entered into state PMDPs by providers.

PDMPs’ capabilities are a patchwork in comparison to the streamlined Pharmacy Prescription Data system requested by the DEA. For example, PDMPs’ data refresh at varying intervals by state, ranging from real-time to daily to weekly updates, as Dr. Peter Kreiner, a senior scientist at Brandeis University’s Institute for Behavioral Health, explained to Filter. The DEA’s software would involve data refreshed each day.

“The impact of including buprenorphine will be appalling for people’s health.”

Scrutiny of OUD treatments will also be applied to prescribers and pharmacists. For the former, the DEA will be able to scrutinize their “percentage of patients receiving an Opioid and Buprenorphine together,” and, for the latter, the “Number of Oxycodone and Buprenorphine within an overlapping window” and “Percentage of scripts that are Oxy Buprenorphine within an overlapping window.”

“The impact of including buprenorphine will be appalling for people’s health,” Dr. Hannah Cooper, the chair of substance use disorder research at Emory University, told Filter. Applying more scrutiny to an already stigmatized medication could deter patients from accessing it and pharmacists from providing it, she said. That would add onto pharmacists’ existing hesitations, or oughtright refusal, to supply buprenorphine, which has been linked by Cooper and colleagues to existing DEA regulations.

Although the Pharmacy Prescription Data system will track individual patients with unique “encrypted identifiers,” the chosen contractor must be able to facilitate a three-business-day retrieval of personally identifying patient information when served with an administrative subpoena by the DEA.

The DEA has a history of exploiting administrative subpoenas to build a mass surveillance apparatus. Pre-dating—and outlasting—the National Security Agency’s infamous bulk telephone metadata collection revealed by whistleblower Edward Snowden, one DEA program, launched in 1992 and apparently still kicking, gathers international phone call data en masse.

The drug-war agency used its administrative subpoena power, according to a 2019 DEA inspector general report, to “collect data in bulk without making a prior finding that the records were […] ‘relevant or material’ to any specific defined investigation”, and it failed to develop “a robust legal review” of its practices. The watchdog agency called the DEA’s conduct “troubling.”

“The idea that patient-level data is available to the DEA is quite frightening. We don’t want to make people worry that their decisions will be monitored by this highly punitive federal agency,” said Cooper. “If you’ve been inhabiting a space where you’ve been persecuted by the federal government for some time, and they now have access to your private medical information, there will be tremendous consequences for population health and health equity.”

WTH ? : In 1973, President Richard Nixon created the Drug Enforcement Administration (DEA) through an executive order

In 1973, President Richard Nixon created the Drug Enforcement Administration (DEA) through an executive order

https://www.jems.com/2009/12/31/brief-history-dea-sup/

In 1973, President Richard Nixon created the Drug Enforcement Administration (DEA) through an executive order that established a centralized command structure to combat “an all-out global war on the drug menace.”[1] Currently, the DEA retains a presence in the U.S. and 63 foreign countries, and has an operating budget in excess of $2.3 billion.[1] The DEA’s stated mission is to “enforce the controlled substances laws and regulations of the United States.”[1] This is accomplished through use of U.S. civil and criminal courts, as well as international courts of competent jurisdiction.

Of increasing importance for health care and EMS providers is a core function of the DEA—”Enforcement of the provisions of the Controlled Substances Act as they pertain to the manufacture, distribution, and dispensing of legally produced controlled substances.”[1] The DEA is particularly concerned with the “alarming prescription drug abuse problem in America.”[2] Under current estimates, more than 6 million Americans abuse prescription meds, which is more than cocaine, heroin, hallucinogens and inhalants combined.[2] Also, more Americans are abusing pain medications (2.4 million) than marijuana (2.1 million) or cocaine (1.0 million).[2] Accordingly, the DEA has set a course and regulatory framework that demands the health-care community be “vigilant in prevention diversion.”[2]

Through passage of the Controlled Substances Act, Congress established a comprehensive framework concerning registering, reporting, prescribing and other regulation of controlled substances to be enforced by the DEA.[3] Congress provided the attorney general the power and authority to both delegate enforcement and promulgate regulations deemed “necessary and appropriate” to regulate all controlled substances. In an effort to accomplish its mission, the DEA created the Office of Diversion Control, which seeks to limit, investigate, prosecute and eliminate diversion of controlled pharmaceuticals and controlled chemicals.[4] The attorney general and DEA have also set forth extensive regulations outlining drug diversion policy.[5]

The Office of Drug Diversion Web site contains an amazing amount of valuable information, including an electronic copy of the Controlled Substances Act and corresponding regulations applicable to drug diversion, registration, etc.[6] Specific questions regarding controlled substances can be addressed to the applicable diversion field office.[7]

Does this mean …. that any President since Nixon resigned on August 9, 1974 … could have “used their pen” to GET RID OF THE DEA ? We have had EIGHT different Presidents since then – from both parties …  Does this suggest that no one bureaucrat/politician believes that the DEA and their 50 yrs war on drugs – regardless of the outcomes of their actions – we should continue to fund them for many more decades to come ?  The only “social war” that we have fought longer is the “war on poverty”…. and spent some 20+ TRILLION dollars in fighting that social war.

Just what we need ANOTHER PRESIDENT with a family member with a substance abuse problem

Biden Opioid Plan Puts Pharmacies On Notice

https://www.law360.com/publicpolicy/articles/1323869/biden-opioid-plan-puts-pharmacies-on-notice

Law360 (November 8, 2020, 5:16 PM EST) — President-elect Joe Biden will enter office with a plan to curb the nation’s opioid crisis by increasing federal investigations into distributors of the drug, signaling that smaller companies should be aware that it’s not just big businesses that can become the focus of federal prosecutors.

Biden delivered a victory speech in Delaware on Saturday night after projected wins in Pennsylvania and Nevada handed him the electoral votes needed to take the presidency. Though President Donald Trump continues to fight in court, Biden is now poised to put into action an opioid plan he announced in March.

Biden’s plan would hold pharmaceutical companies, executives and others accountable for contributing to the opioid crisis, which has killed more than 750,000 people in the country since 1999 from overdoses, according to the Centers for Disease Control and Prevention.

While larger companies such as Purdue Pharma LP have so far been the subject of U.S. Department of Justice investigations and the target of civil suits, smaller companies should heed the message that no one in the opioid market is safe, said Jodi Avergun, the head of Cadwalader Wickersham & Taft LLP’s white collar defense group and a former U.S. Drug Enforcement Administration counsel.

“This is a message that no one in the market is safe from these responsibilities … [and] once opioid cases are settled in the current MDL, all of the scrutiny will go away from the whole issue,” she said. “This is a warning to middle-market companies who might not have been wrapped up in an all-consuming basis in the opioid litigation.”

The federal multidistrict litigation consolidated in Ohio contains roughly 3,000 cases filed by cities and counties, as well as Native American tribes, that want money for health care and law enforcement costs related to the opioid epidemic. The suits accuse the opioid manufacturers, distributors and pharmacy chains of feeding the epidemic by downplaying the risks of addiction and failing to monitor suspicious orders.

Under the Trump administration, the DOJ’s focus has only been on a relatively small number of participants in the DEA’s registry. Conversely, Biden’s policy tells government investigators to make sure companies are complying with regulations for monitoring and reporting suspicious orders of opioids, Avergun said.

“The next wave of enforcement actions is going to be who else is there beside the primary [manufacturers], distributors and pharmacy chains,” she said.

Product liability attorney and Bradley Arant Boult Cummings LLP partner Jay Stroble pointed out that Biden has said he would instruct his attorney general to support municipalities that have sued oil companies over climate change, so it may be that the DOJ under Biden would become more “activist.”

Attorneys also noted that investigations into pharmaceutical companies over their opioid marketing and distribution are popular on both sides of the political divide.

“There’s this sense of going after the big pockets and getting these big press releases, sometimes with good reason, looking for a deterrent to try to change behaviors,” said Larry Cote of Cote Law PLLC, a former DEA compliance attorney.

During the last months of the Obama administration, the DOJ made a $150 million deal with McKesson Corp. and a $44 million deal with Cardinal Health Inc. for failing to report suspicious opioid orders.

The Trump administration also moved aggressively against opioid companies, making it a top priority in 2017 when Trump declared the opioid crisis a national emergency. Since then, the DOJ has pursued investigations into opioid companies and reached settlements with multiple companies, most recently with Purdue. That October agreement includes the company’s guilty plea to three felony counts, $8 billion in financial penalties, and the dissolution of the company and the Sackler family’s ownership interests in it.

Still, attorneys questioned the wisdom of pursuing actions against pharmaceutical companies without meaningfully addressing other issues related to the opioid crisis, such as prevention and prescriber education.

“We’re living through a time where the drug companies are still the villains,” Harry Nelson of Nelson Hardiman LLP said.

The coronavirus pandemic has also caused a surge in opioid overdoses, according to the Overdose Mapping Application Program, which is run by the University of Baltimore. Reports of suspected opioid overdose submissions rose by 18% following lockdown orders in March, according to the program.

“If you look at the numbers, it becomes impossible to avoid the link between all the isolation and despair and trauma of the last six, seven months,” Nelson said.

But those overdoses have been largely caused by illicit drugs, including nonprescription fentanyl, according to the American Medical Association. There was also a nearly 40% drop in opioid prescribing between 2017 and 2019.

“The whole problem on a supply-side level is fentanyl, not prescriptions,” Nelson said.

Nelson, who authored a book on the opioid crisis and talked to Vice President-elect Kamala Harris’ campaign during the primaries about opioids, said that while he saw nothing negative in Biden’s plan, there’s too narrow a focus on pharmaceutical companies and there should be more of a focus on early intervention and prescriber education.

“I think the pharmaceutical industry has learned its lesson,” Nelson said. “And now the crisis has changed. You have patients who are genuinely in pain who aren’t getting access to medication.”

Biden’s plan does call for more education, Cote said, but that’s been proposed before and there’s always a question of who will fund it: the DEA or the U.S. Food and Drug Administration.

Cote said that distributors could opt to drop out of the opioid market if they decide there’s too much risk of investigation, and it’s not worth the risk of the cost of running that part of their business.

One marked difference between Trump, whose brother Fred died of alcohol addiction, and Biden is that Biden has been open about his son Hunter’s struggles with addiction, saying that he was proud of Hunter during one of the debates, Nelson said.

“His comments … hold out the hope of somebody who really understands this in a lived way,” he said. “So I think that he can help reduce the shame that people feel, that families feel.”

HHS Proposes Unprecedented Regulatory Reform through Retrospective Review

HHS Proposes Unprecedented Regulatory Reform through Retrospective Review

https://www.hhs.gov/about/news/2020/11/04/hhs-proposes-unprecedented-regulatory-reform-through-retrospective-review.html

Today, the Department of Health and Human Services issued a notice of proposed rulemaking requiring the Department to assess its regulations every ten years to determine whether they are subject to review under the Regulatory Flexibility Act (RFA), which requires regular review of certain significant regulations. If a given regulation is subject to the RFA, the Department must review the regulation every ten years to determine whether the regulation is still needed and whether it is having appropriate impacts. Regulations will expire if the Department does not assess and (if required) review them in a timely manner.

“For decades, Presidents have said agencies should retrospectively review their regulations. Under President Trump, HHS is actually doing it,” said HHS Secretary Alex Azar. “Our proposed rule is an effective way to deliver on the requirements of the Regulatory Flexibility Act, signed by President Carter and on the books since 1980. With HHS regulatory responsibilities as wide-ranging as food safety, drug approval, adoption and childcare, and healthcare financing, it’s essential that we know—and inform the American people—whether we’re executing on these responsibilities in a way that maximizes benefits, minimizes costs, and keeps up with the times.”

“This proposal—the boldest and most significant regulatory reform effort ever undertaken by HHS—would sunset burdensome regulations unless their necessity is publicly demonstrated to the American people,” said HHS Chief of Staff Brian Harrison.

Under the proposed rule, any regulation issued by HHS (with certain exceptions) will cease to be effective ten years after it is issued, unless HHS performs a plenary assessment of the regulation and a more detailed review of those regulations that have a significant economic impact upon a substantial number of small entities.  

That is, all HHS regulations, with certain exceptions (detailed below) will be subject to a two-step review: 1) assessing whether they have a significant economic impact on a substantial number of small entities, the standard set out under the RFA; and, if it qualifies for review under the RFA, 2) a more detailed review that will consider, as prescribed in the RFA, (i) the continued need for the rule, (ii) complaints about it, (iii) the rule’s complexity, (iv) the extent to which it duplicates or conflicts with other rules, and (v) whether technological, economic, and legal changes favor amending or rescinding the rule.

Retrospective review of the costs and benefits of federal regulations has long been a goal of Presidents and regulatory experts across the political spectrum.

When agencies impose regulations, they make projections about the regulation’s impact on the public. Once a rule has been in place, agencies should test those projections and see what real-world impact the regulation is having, and amend or rescind if appropriate.  This proposed rule would incentivize HHS to conduct these performance reviews of its regulations to ensure that rules are delivering the benefits projected in view of the best available science, data, and evidence. An artificial-intelligence-driven data analysis of HHS regulations found that 85 percent of Department regulations created before 1990 have not been edited.

Certain regulations are exempt: regulations that are jointly issued with other agencies, regulations that legally cannot be rescinded, and regulations issued with respect to a military or foreign affairs function or addressed solely to internal management or personnel matters (two categories exempt from standard rulemaking requirements under the Administrative Procedure Act). Regulations that affect the regulations of other agencies will be reviewed in conjunction with those agencies.

This proposed rule seeks to increase transparency, public participation, and democratic accountability. As part of the review process, the public can submit comments on the impacts of regulations.

The proposed rule will be subject to a public comment period. There will also be a public hearing on this proposed rule. Depending on the public comments, HHS could finalize a version of this rule after the public comment period concludes.

Read the proposed rule here

Further Background

What authority does HHS have for this regulation?

The statutory authorities are the statutory authorities for the department’s existing regulations.  HHS is simply amending its regulations to add expiration dates unless the department periodically conducts the required assessment or review of its regulations or an exception applies. 

How will the public be able to comment on the many different regulations affected by this regulation?

There will be a public comment period and a public hearing on this proposed rule.  In addition, if this proposed rule were finalized, HHS will launch a website that will enable the public to easily submit comments on particular rules and select particular rules that they would like to suggest be reviewed.

What historical precedent is there for this rule?

Every President since Jimmy Carter has made efforts toward periodic retrospective reviews of regulations.

  • President Carter: Executive Order No. 12044, in 1978, directed agencies to “periodically review their existing regulations,” requiring agencies to consider, among other things, whether “technology, economic conditions or other factors have changed in the area affected by the regulation.”
  • President Reagan: Executive Order 12291, in 1981, ordered agencies to “review[] existing regulations” in view of cost-benefit principles and potential alternatives. Executive Order 12498, in 1985, ordered agencies to create an annual plan of review for existing regulations.
  • President George H.W. Bush: The 1992 “Memorandum on Reducing the Burden of Government Regulation” instructed agencies to conduct a 90-day review “to evaluate existing regulations and programs and to identify and accelerate action on initiatives that will eliminate any unnecessary regulatory burden or otherwise promote economic growth.”
  • President Clinton: Executive Order No. 12866 called for review of existing regulations to determine whether they have become “unjustified or unnecessary as a result of changed circumstances,” and “to confirm that regulations are both compatible with each other and [are] not duplicative or inappropriately burdensome in the aggregate” and requiring agencies to submit a plan to the White House Office of Information and Regulatory Affairs (OIRA) for period reviews.
  • President George W. Bush: A report – PDF to Congress in 2001 reviewed how to assess the costs and benefits of existing federal regulations, including their aggregate costs.
  • President Obama: Executive Order No. 13563 ordered agencies “[t]o facilitate the periodic review of existing significant regulations . . . to promote retrospective analysis of rules that may be outmoded, ineffective, insufficient, or excessively burdensome, and to modify, streamline, expand, or repeal them in accordance with what has been learned.”

What policy reasons are there for retrospective review of regulations?

Across the political spectrum, experts have recognized the tremendous benefits from retrospective review.   

Cass Sunstein, President Obama’s OIRA administrator, has praised the value of retrospective. Professor Sunstein has written – PDF exit disclaimer icon that “if it is firmly institutionalized, the requirement of retrospective analysis might well count as the most important structural change in regulatory policy since the original requirement of prospective analysis during the Reagan Administration.” Michael Greenstone, former chief economist on the Council of Economic Advisers under President Obama, has written – PDF exit disclaimer icon, “[t]he single greatest problem with the current [cost-benefit analysis] system is that most regulations are subject to a cost-benefit analysis only in advance of their implementation. … This is the point when the least is known and any analysis must rest on many unverifiable and potentially controversial assumptions.”

Douglas Holtz-Eakin, former director of the Congressional Budget Office and staff economist on the Council of Economic Advisers under President George H.W. Bush, has said – PDF that “there needs to be a formal and systematic retrospective review of existing rules in order to, on a regular basis, answer the question, is this regulation still a good idea?”

The Organization for Economic Cooperation and Development has recommended exit disclaimer icon that countries not only undertake retrospective review, but also consider the use of sunset clauses to incentivize it. Other countries and numerous states have also implemented retrospective review of regulations.

Despite widespread agreement that retrospective review yields tremendous benefits, HHS has not reviewed many significant regulations. This proposed rule would incentivize the Department to perform these reviews

What are some examples of outdated regulations?

An artificial-intelligence-driven data analysis of HHS regulations found that 85 percent of Department regulations created before 1990 have not been edited; the Department has nearly 300 broken citation references in the Code of Federal Regulations (CFR), meaning CFR sections that reference other CFR sections that no longer exist; more than 50 instances of regulatory requirements to submit paper documents in triplicate or quadruplicate; and 114 parts in the CFR with no regulatory entity listed, 17 of which may be misplaced.

During the pandemic, HHS has suspended numerous regulations based on the judgment that they impose unnecessary costs impeding the response. Under the proposed rule, these rules would have to be regularly reviewed to determine whether they make sense in ordinary times, too. Examples of these regulations include the types of communications technologies that are HIPAA-compliant and available for use in telemedicine; restrictions around the practice of medicine across state lines; and regulations on benefits and support hospitals can provide to their medical staffs, such as meals, laundry service for personal clothing, or child care, while staff are at the hospital and engaging in activities that benefit the hospital and its patients.

Some elements of HHS have conducted substantial and successful retrospective reviews under the Trump Administration. For instance, the Centers for Medicare & Medicaid Services has reduced the number of Medicare quality measures physicians are required to report by 18 percent since 2017 by eliminating measures where results were “topped out,” duplicative, or not meaningful enough to justify the cost.

What happens if a regulation is not reviewed within the timeframe required?

It expires. If the agency publishes a review concluding that a regulation should be rescinded or amended, the agency will have two years to rescind or amend the rule.  When the review determines that a regulation should be amended or rescinded, the Department would also, on a case-by-case basis as appropriate, use enforcement discretion to not enforce the regulation or a portion of the regulation until it is amended or rescinded. The proposed rule specifically asks for input on what procedures would make the most sense in these situations.

Will this rule cut federal regulations?

The goal of the rule is to ensure that regulations benefit the American people as intended. In some cases—the plurality of cases, in one OMB sample—the projected benefits of a regulation may be overstated. In other cases, the benefits may be understated, or the costs under- or overstated. Retrospective review provides powerful ways to understand costs and benefits, as well as to assess cumulative costs from multiple regulations that may be difficult for regulators to anticipate in advance.

The Trump Administration and HHS leadership are committed to ending federal regulations that fail to deliver benefits to the American people in the least burdensome way possible and at minimum cost. At the same time, as demonstrated by efforts in areas like price transparency, HHS is committed to regulations that facilitate patient-centered markets to deliver more choice, better care, and lower costs, and to regulations that protect lives and promote independence.

Retrospective review helps determine whether those goals are being accomplished and whether regulations intended to accomplish them should be maintained, amended, or rescinded.

Why take this action now, while much of the administration and HHS are engaged in fighting COVID-19?

While many HHS employees are focusing on the COVID-19 response full- or part-time, the Department has also been able to continue moving forward on a range of priorities to enhance and protect the health and well-being of the American people.

Further, this is a proposed rule, so it will have no impact on HHS in the short term.  As explained in detail in the proposed rule, even once finalized, the proposed rule is not expected to increase burdens significantly on HHS.  Rules must only be reviewed within ten years after their enactment or two years from the finalization of this rule, whichever is later.

For over 40 years, Presidents and Congress have been calling for retrospective review.  HHS believes it is long overdue to begin implementing this intent. In May 2020, the President issued Executive Order 13924, directing all agencies to examine opportunities for regulatory reform to support the economic recovery from the recession caused by COVID-19. President Obama’s Executive Order No. 13610 similarly provided that retrospective review has particular relevance “[d]uring challenging economic times.”

Will reviewing regulations create unnecessary or impractical burdens on HHS agencies?

No. The proposed rule explains how HHS can perform the required assessments and reviews at little cost. Agencies such as the Centers for Medicare & Medicaid Services already update significant amounts of regulations each year, including through annual payment rules. The Department estimates investing approximately $10 to $26 million in this effort over ten years.  HHS’ annual budget is more than $1 trillion.”

Why propose a rule requiring review of all regulations, rather than just the regulations considered significant under the RFA?

This proposed rule follows in the footsteps of the RFA. Without performing an initial assessment, the Department cannot know which regulations have or will have a significant economic impact upon a substantial number of small entities. Prospective analyses are imperfect and circumstances sometimes change.

Why use a sunset provision rather than some other incentive?

It is widely recognized that strong incentives are needed to institutionalize retrospective review.  For 40 years, other attempts short of a sunset provision have been largely unsuccessful at getting agencies to perform retrospective reviews.

A report by the Congressional Research Service concluded exit disclaimer icon that, “[w]ithout some type of enforcement of the review requirement, agencies are unlikely to conduct many more reviews than have occurred pursuant to Section 610.” One analysis – PDF exit disclaimer icon of regulation in all 50 states found that, for promoting active regulatory reform, “[t]he single most important policy in a state is the presence of a sunset provision.” New Jersey and Indiana, for instance, impose a seven-year sunset provision on regulations; North Carolina uses a ten-year period. Foreign nations such as the United Kingdom, Germany, France, and the Republic of Korea have also used sunset provisions.

Has HHS undertaken such reviews of its regulations before?

In addition to the regulatory reviews that have led to reforms under the Trump Administration, such as CMS’s Meaningful Measures Initiative and finalized changes to 42 C.F.R. Part 2, the Obama Administration undertook regular limited reviews of some HHS regulations in response to Executive Order 13563.

Why is HHS publishing this rule now?

The Department has been working for a long time to determine ways to better institutionalize retrospective review. Once HHS has cleared a proposed rule through the Office of Management and Budget review process, it releases it for public comment so that the rulemaking process can move forward.

How many regulations will the proposed rule initially apply to during the two-year window? Would the proposed rule apply to every regulation issued by any HHS entity that is 10 years or older—except the regulations already identified as exempted?  If so, how many is that?

Under this proposal, rules issued by an HHS component that are more than ten years old would need to be reviewed within two years after this proposed rule is finalized.  The Department estimates that roughly 2,480 rulemakings would need to be reviewed in this two-year window.  The proposed rule explains how this can be done and the resources required for this effort.

Will any of this notice of proposed rule-making be able to be finalized if the President does not have a second term?

Whether HHS finalizes this rule, and the timeframe for doing so, depends upon the comments received during the public comment period.

Won’t the constant review of regulations create uncertainty for those subject to the regulations (which is often cited as a cost of regulation itself)?

The Department maintains that the benefits of retrospective review outweigh the costs of uncertainty. The proposed rule also addresses concerns about uncertainty and reliance interests in at least two ways. First, as you note, through public notices posted via the HHS website, the public will (a) be apprised of which rules are under review and, by extension, rules subject to expiration; (b) be allowed the opportunity to comment on the same; and (c) be able remind HHS to assess or Review any rules that might be nearing expiration. Second, to the extent the Department revises or modifies a regulation after conducting an assessment or review under the proposed rule, then HHS would take reliance interests into account at that time.

Is it time for a new GAME PLAN ?

I can’t count the number of times that members of the community have stated that they have written their member of Congress about the being denied appropriate medical treatment for their pain… only to have the member of Congress to response with a letter with “canned paragraphs” about the opiate addiction crisis that has to be addressed ?

Likewise, can’t count the times that pts have stated that they must submit to certain procedures – especially ESI’s – or they will not be getting any oral opiates and/or discharged from the practice.

It is reported that there are 10 million ESI’s given to pts every year and abt 5% of these ESI’s will cause the pt to contract https://www.practicalpainmanagement.com/pain/spine/arachnoiditis-part-1-clinical-description

Often repeating these ESI’s provide little/no pain relief to the pt… but can possibly produce some long term additional problems for the pt.

While COVID-19 is the CURRENT CRISIS… there is another CRISIS on the horizon that no one is talking about..

No one is talking about all the taxes that various cities, counties, states and the feds have failed to generate because of COVID-19.  Nashville, TN has already raised their property tax rates by 34 %.

If more “financial relief” is provided in the next few months… our country will accumulate abt another 10 trillion… on top of the extra 10 trillion the feds spend during the 8 yrs of Obama and the original 10 trillion that our federal debt grew between 1776 and 2008 (Bush 43).

So how does 30 TRILLION national debt effects everyone’s life ?

Could getting that much national debt…  be like a earthquake that creates a tsunami – and you live on the coast… and then there are aftershocks – second earthquakes – that are large enough to create a second tsunami  –  think minimum wage of $15/hr and another after shock so great that it creates another after shock so great that it creates a third tsunami – think healthcare for all  – with no premiums, not deductibles and no copays … for anyone person in our country legals and illegals.

If that doesn’t create massive inflation… nothing will… and in turn the Federal Reserve will be forced to INCREASE the national interest rate… meaning that the interest that is due on our national debt will remind you of the launch of the space shuttle … going straight up !

Maybe it is time to talk to Congress about the 10 billion- 30 billion/yr that is being spent on ESI’s… and practitioners that keep providing these procedures that provide no relief to the pt… that is considered providing and charging for medical services/procedures that are not medically necessary… and there are many COUNTRIES that have banned the administration of the class of medication corticosteroids via ESI’s.  In the good ole USA… both the FDA and Pfizer have not recommended/discouraged the use of corticosteroids in ESI’s.

It is also illegal https://medtrade.com/news/billing-reimbursement/beneficiary-inducement-statute-two-important-exceptions/ to encourage  -give an inducement for – Medicare/Medicaid pts to participate in a service or procedures that has no medical benefit…  Thinks of the promise of the prescriber giving the pt a Rx for oral opiates as an inducement to submit to a ESI procedures using corticosteroids.  Not to mention the cost of treatment of the adhesive arachnoiditis that some pts will end up with.

The FDA has come out and stated that pharmacy compounded meds should be used in implanted pumps.  There is only one opiate that is approved by FDA for use in implanted pumps Infumorph (Morphine) and Medtronics has done stability studies and this medication will maintain at 90% potency for SIX MONTHS in an implanted pump.  There has been some small studies that some of the pharmacy compounds opiates will lose up to 50% of their potency within 3 months of being placed into a implanted pump.

If nothing else, these pts are having to have their pumps refilled every 60 to 90 days… instead of six months…that means that Medicare/Medicaid is paying up to 4 MORE TIMES to have their pumps filled because the practitioner uses a pharmacy compounded product.  How many of us would buy medication(s) that could possibly lose 0.5% of its potency EVERY DAY ?

The DEA are raiding practitioners’ office that have been prescribing oral opiates to pts and charging the prescriber for Medicare/Medicaid fraud…  and other charges .. billing for medication that the DEA has deemed NOT MEDICALLY NECESSARY.

Maybe the community should start a conversation about all the tens of billions of dollars that Medicare/Medicaid for services/procedures that are discouraged and in many cases are not medically necessary.

Should Congress consider pushing the FDA to ban ESI’s using corticosteroids and get Medicare/Medicaid to declare that these procedures are “experimental”… and Medicare/Medicaid do not paid for experimental treatments and whatever Medical/Medicaid does… the rest of the insurance industry usually follows.

The same thing should be done on pharmacy compounded meds for implanted pump and either banned out right or label their use as “experimental”

It really doesn’t matter who ends up being our President for the next four years…. it really doesn’t matter which party is the majority in the Senate/House…  the community needs to start this conversation with members of Congress as soon as the next Congress comes to power… So when the “financial tsunami” of the COVID-19 crisis comes ashore…

Maybe as some of these non-profits that some chronic pain groups are creating could petition the FDA,  Medicare, Medicaid to change the status of these products. Has nothing to do with treating pain or providing opiates… it is all about tens of billions of dollars that are being spent that are either illegal or done without medical necessity.

 

Face book community standards are so full of tubular brown STUFF

We can’t review your comment a second time
Since you requested a review, many people and organizations around the world have been affected by the coronavirus (COVID-19) pandemic. Facebook is also affected.
We have fewer people available to review content. For this reason, we’re unable to review content more than once right now.
Since we can’t review your post again, we can’t change our decision.
Thank you for understanding.
If you disagree with Facebook’s decision, you can appeal to the Oversight Board using this reference ID. The board chooses certain Facebook decisions to review, focusing on those that are the most challenging and globally relevant. You have until November 20, 2020 to appeal.
Oversight Board Reference ID: FB-F12ON47Y
Learn about the Oversight Board and how to appeal

What is the likelihood my case will be reviewed?


The Oversight Board will select which cases to review based on complexity and global significance. Due to volume, only a small number of submitted cases will be heard.

The above graphic was used in a comment on FACE BOOK in NOV 2019 and they are just now telling me that it violates community standards. I could have inserted a pic of just about any politician and it would be true.

Why in the hell do they have a REVIEW PROCESS if they know damn good and well that they are “under staffed” because of COVID-19.. what else can we blame on COVID-19 ?

He has promised that no one earning < $400,000/yr will have their taxes increased.   Yet he has stated that he is going to rescind Trump’s tax cuts…. which went to a lot of people earning < $400,000

If Biden becomes our next President… I hope that people hold his feet to the fire when he promised to protect us from EVERYTHING SEEN AND UNSEEN..  Has any of you seen a COVID-19 virus up close and personal ?

He is promising many people will get a $14,000/yr pay raise – that is a minimum wage of $15/hr – abt $30,000/yr – claims that it is minimum living wage… yet a person on Social Security gets about $18,000/yr and a person on Medicare disability gets <  $10,000/yr.

If this increase in minimum wage makes the price of  your favorite fast food sandwich goes up $1.00 –  that is not a tax – right ?

He states that he is behind a  “green new deal” and we will have to start buying our energy from countries that don’t particularly likes us and could compromise our country’s safety… I remember during the Obama/Biden administration when GASOLINE was > $4.00/gal…    I just drove back from our FL condo today and paid as low as $1.77/gal for fuel.  A round trip to our condo is about SIXTY GALLONS of fuel…  Could $120 -$150 extra cost for fuel put a BIG DENT into a lot of families’ vacation plans ?  Not to mention all the increased costs in various things that families purchase on vacation.

Recently, I saw a new definition of POLITICS

POLI = much/many

TICS = blood suckers

so it would appear that politicians are nothing but a BUNCH OF BLOOD SUCKERS

Portsmouth doctor reprimanded for treatment of chronic pain patient

Portsmouth doctor reprimanded for treatment of chronic pain patient

https://www.unionleader.com/news/health/portsmouth-doctor-reprimanded-for-treatment-of-chronic-pain-patient/article_d45611d5-f0e3-5a8f-ace5-46bc9d945c90.html

CONCORD — A Portsmouth doctor has been reprimanded and fined by the New Hampshire Board of Medicine after he cut back a chronic pain patient’s prescription opioid painkillers — and then dropped him as a patient altogether after the man threatened suicide.

Joshua Greenspan, who is board certified in pain management and anesthesiology, signed a settlement agreement in May to resolve allegations of professional misconduct. Greenspan did not respond to a message left at his office at the American Pain Institute on Friday.

According to a settlement agreement, the Board of Medicine received a complaint from a patient in June 2018, alleging that Greenspan, “after treating him for years and prescribing the same dosages of pain medication, suddenly reduced his medications, which led to increased pain and anxiety, and suicidal ideations.”

The case cuts to the heart of a growing controversy over recent federal guidelines for prescribing opioid painkillers. Chronic pain patients who have relied on prescription painkillers for years, sometimes decades, say they are being caught up in efforts by government agencies, doctors, pharmacists and insurance companies to reduce the volume of opioids being prescribed in response to the ongoing drug epidemic.

Chronic pain patients previously have told the Sunday News that many doctors in New Hampshire have begun “tapering” them off the medications that allow them to go about their daily lives. And they say some patients have taken their own lives.

The Centers for Disease Control and Prevention estimates that 19.6 million Americans suffer from “high-impact” chronic pain, defined as pain that interferes with daily life or work activities.

In the recent Board of Medicine case, the patient has suffered chronic pain for years and had been a patient of Greenspan since 2014.

A previous doctor had prescribed 80 mg of Oxycontin twice daily and 30 mg of Oxycodone four times a day, and Greenspan continued to prescribe those painkillers at the same doses.

Greenspan checked the prescription drug monitoring database, which tracks prescriptions of controlled drugs, and the patient was subject to urine tests and pill counts to make sure he wasn’t misusing the medications, according to the settlement.

On April 9, 2018, Greenspan informed the patient that the Centers for Medicare and Medicaid Services (CMS) had issued new guidelines that allowed doctors to prescribe only up to the equivalent of 90 mg of morphine a day. He told the patient that he was reducing his dosage of Oxycontin to come into compliance with those guidelines, and cut the man’s daily dosage by 40 mg.

The board’s order noted that the CMS guidelines did not actually set an upper limit but required pharmacists filling prescriptions for higher amounts of opioids to discuss such cases with the prescribing physicians.

According to the settlement documents, Green- span’s patient reported that his pain was not controlled by the lower dosage and he was having a “tough emotional time.” Later that year, the patient failed a pill count and was admitted to a hospital for threatening suicide.

That’s when the doctor told the patient he was no longer comfortable prescribing opioids for him and would no longer treat him. He also “reported his concerns about (the patient’s) well-being” to the local police department and the man’s primary care doctor, according to the settlement. He also sent a prescription for an opioid withdrawal drug to the patient’s pharmacy.

The board found that Greenspan’s handling of the case violated ethical standards of professional conduct. In addition to reprimanding him and fining him $1,000, the board required him to participate in at least 12 hours of education in prescribing opioids for pain management and in pain management record-keeping.

Bill Murphy, a Hooksett man who is active in the Don’t Punish Pain movement, called the Board of Medicine’s action “a great step in the right direction.”

“It just sends the right message to physicians in New Hampshire that the guidelines are just that — guidelines — and not hard and fast rules,” he said.

It’s a message doctors need to hear, as many fear being disciplined for prescribing too many opioids, Murphy said.

“I think in the end they do want to help people,” he said. “They feel like they’re caught between a rock and a hard place.”

District Leader Telling Pharmacists Ignore CDC Flu Vaccine Recommendations

District Leader Telling Pharmacists Ignore CDC Flu Vaccine Recommendations.

https://www.youtube.com/watch?v=KKqXmyt-yJQ&feature=emb_logo

I doubt if most pts that patronize CVS, Walgreens and other chain pharmacies realize that the Pharmacist/Rx dept have monthly quotas of various vaccinations that the Pharmacist/pharmacy can legally provide.

This audio is a audio recording of a CVS district manager (DM) with untold number of CVS pharmacist in a conference phone call… over the various Rx depts not meeting their flu shot quotas.

I got the impression that this quota was for period that included August. This DM – his accent I considered is rather “thick ” – is reminding the pharmacists that “you are DOCTORS too”.  Which to me suggests that the DM is not a pharmacist and from medical perception is CLUELESS. but he is probably just following the edicts from the corporate suite … that they have flu vaccine inventory on hand in August …so they need to start pushing promoting giving flu shots.  Don’t want to have flu vaccine on hand when the flu season is over, that they have to pay for and will have to throw it away at the end of the season, because it will not be appropriate for the next year’s flue season.  Besides, as one pharmacist put it … they might be able to get pts to get a “booster flu shot” in January because they got their flu shot so early and the antibodies would be diminishing below therapeutic levels.

Even when one or more of the pharmacists pointed out that the CDC recommendation is for flu shots to be given starting in Oct…. the DM pushes back about ignoring CDC guidelines..  Personally, we don’t get our flu shots until last week of Sept – first week of Oct. Typically the pharmacy has a good supply of vaccines at that time of the year…  the longer a pt waits to get their flu shot the more likely they may run into supply problems..  It takes about 6 months for the pharmas to “make” flu vaccines.  So if demand is more than they anticipated, they can’t just “make more” for this particular winter season.

The CDC does not actually keeps records of flu related deaths, but yearly “estimates” range up to 60,000…depending on the year.

This is not new, a few years ago we were visiting our Daughter/Grandson in Durham, NC and we went into a Target – after CVS had taken over the in house Pharmacy operations – It was early August and there was a female (tech/cashier) from the Rx dept at the front door … “pushing ”  people walking in the front door – no where near the Rx dept – into getting flu shots.

I have been told that these chain pharmacists are told that if the only way to make their quotas is to contact large employers, nursing homes etc. etc and set up “flu clinics” AND they need to schedule these clinics ON THEIR DAY OFF… so the chain pharmacy is generating a profit and the pharmacist is expected “to do it off the clock “

I have  been told that CVS in particular claim that their pharmacists are a hybrid Salary/Hourly employee… whichever allows CVS to pay the pharmacist the lesser amount of money for a particular pay period.  Of course, with these flu clinics … the pharmacist that pay period are considered SALARIED… so that they don’t have to be paid for working on their day off…

 

Medtronic to pay $9.2M over alleged kickbacks involving 100+ events at surgeon’s restaurant

Medtronic to pay $9.2M over alleged kickbacks involving 100+ events at surgeon’s restaurant

https://www.beckersspine.com/orthopedic-a-spine-device-a-implant-news/item/50325-medtronic-to-pay-9-2m-over-alleged-kickbacks-involving-100-events-at-surgeon-s-restaurant.html

Medtronic USA will pay over $9.2 million to settle allegations that it footed the bill for expensive events benefiting South Dakota neurosurgeon Wilson Asfora, MD, to induce him to use certain implantable devices, the Department of Justice announced Oct. 29.

Medtronic agreed to pay the U.S. $8.1 million to resolve allegations that it violated the False Claims Act, plus $1.11 million to settle allegations that it violated the Open Payments Program, which requires medical device manufacturers to make CMS aware of certain payments or transfers of value to a physician.

The federal government accused Medtronic of agreeing to Dr. Asfora’s request that it pay for social events at Carnaval Brazilian Grill — knowing that Dr. Asfora owned the restaurant and would invite business partners, social acquaintances, favored colleagues and potential and existing referral sources — to induce him to use the company’s SynchroMed II intrathecal infusion pumps.

Over a nine-year period, Medtronic allegedly paid for more than 100 events at Dr. Asfora’s restaurant and did not properly report these payments to CMS. While Medtronic reached a settlement with the U.S. regarding these allegations, there has been no determination of liability.

Once the alleged wrongdoing came to light, Medtronic fired a sales representative and sales manager, according to the DOJ. Twelve other employees involved in the alleged misconduct were disciplined.

As part of the settlement, Medtronic agreed to cooperate with the DOJ’s investigations of and litigation against other parties.

Dr. Asfora and two of his other companies are defendants in a separate lawsuit in which the U.S. became involved in November 2019. That lawsuit concerns allegations Dr. Asfora received kickbacks to use certain implants in his spinal surgeries, in violation of the False Claims Act.

‘Open Notes’ Rule Delayed Until April

‘Open Notes’ Rule Delayed Until April

https://www.medpagetoday.com/publichealthpolicy/generalprofessionalissues/89384

Feds point to limited healthcare IT resources spurred by COVID as reason for delay

Implementation of the federal “Open Notes” rule granting patients immediate access to their clinical notes, originally slated for Monday, has been postponed until next spring, a Department of Health and Human Services official said.

The deadline has been extended to April 5, 2021, to give providers who are busy with the demands of COVID-19 and the move to telehealth more time to comply with the rule, Don Rucker, MD, National Coordinator for Health Information Technology, said on a press call.

“This was really based on priorities that providers have set with their limited healthcare information technology resources,” Rucker said. “That was the gating activity.”

Susan Bailey, MD, president of the American Medical Association, said that her organization wrote to the Office of the National Coordinator for Health Information Technology to request additional time for physicians to comply with the rule.

“Given the widespread impact these rules will have, it is crucial that physicians are given both time and additional guidance,” Bailey said in a statement. “The AMA will continue working with ONC to provide clear and usable resources to help physicians and their medical practices understand and implement these requirements.”

The “Information Blocking” rule of the 21st Century Cures Act, passed in 2016, was supposed to go into effect on Nov. 2. Referred to as “Open Notes,” it states that eight types of clinical notes can’t be blocked and must be made immediately available to patients. These include:

  • Consultation notes
  • Discharge summary notes
  • History and physical
  • Imaging narratives
  • Lab report narratives
  • Pathology report narratives
  • Procedure notes
  • Progress notes

Psychotherapy notes, and information compiled in anticipation of a lawsuit, are exempt from the rule.

“Patients have had the right to see their medical record, but it hasn’t been easy, in general, for them to do that,” said Catherine DesRoches, DrPH, executive director of OpenNotes, a study group that launched early trials of the practice. “This gives patients easy and convenient access to all of their medical information through a patient portal.”

In 2010, the OpenNotes program began as a collaboration between Beth Israel Deaconess Medical Center in Boston, Geisinger Health System in Pennsylvania, and Harborview Medical Center in Seattle. With funding from the Robert Wood Johnson Foundation, they launched an exploratory study of 105 primary care doctors who invited 20,000 of their patients to read their notes via a secure online portal.

The results, published in the Annals of Internal Medicine in 2012, found that doctors reported little change in workload, and “few turned off access to notes after the pilot was over,” DesRoches said. Patients were happy with the ability to see the notes and few reported being worried or confused by them.

Since that study, numerous hospitals and health systems have implemented an open-note policy, DesRoches said. Today, more than 250 healthcare organizations grant such access to more than 53 million patients, she said.

Among those organizations are the U.S. Department of Veterans Affairs, the Mayo Clinic, the MD Anderson Cancer Center, and Sanford Health. “These were all early innovators who can serve as examples for other organizations,” DesRoches said.

UCHealth in Colorado has used Open Notes since 2016. CT Lin, MD, chief medical information officer of UCHealth, said the new rule requires additional reporting, even for his institution. While UCHealth already provides many types of notes immediately, it delays several types of results, including reports like neonatal screens, cytology results, and mammograms for a range of 4 to 14 days.

Despite the high number of early adopters, providing immediate access to notes will be uncharted territory for many healthcare organizations and physicians who have raised several concerns, such as notes being misinterpreted or second-guessed by patients.

It could also mean taking more time to write notes differently so that patients can understand them, which could mean more work for already overstretched clinicians, some have argued.

Still, more physicians have seen the upside. Ziad Gellad, MD, MPH, of Duke University in Durham, North Carolina, tweeted, “My patient care is better because of the feedback patients have given on my notes — forgotten allergies, missed exposures, and clarity on our plan to name a few.”

“I think this is going to force health professionals to help patients think about information and what they do with it,” Bryan Vartabedian, MD, of Baylor College of Medicine/Texas Children’s Hospital in Houston, wrote on his blog 33 Charts. “It will force patients to recognize the difference between information and knowledge and wisdom. I suspect that the most critical ultimate change will be transparent conversations and more timely physician follow-up on high stakes studies.”